Halopemide is a non-specific PLD2 inhibitor that can reduce prostate cancer cell-derived exosome secretion and incapacitate these exosomes to stimulate the proliferation and mineralization of osteoblasts. The gene discussed is PLD2; the disease is Familial prostate cancer.